

Applied DNA Sciences' Instant Detection Device Program Leads to Development of Next Generation SigNature DNA Platform

STONY BROOK, N.Y., April 30, 2009 /MarketWire/ -- Applied DNA Sciences, Inc. (OTC Bulletin Board: APDN) today announced that Phase 1 development of a proprietary new instant detection device has been successfully completed. This new detector offers greater sensitivity while still being able to reliably operate in the field under harsh conditions. Conducted in partnership with the Center for Advanced Technology in Diagnostic and Sensor Systems ("SensorCat") at Stony Brook University, this program was co-funded through a grant to APDN.

"Combined with our forensic authentication services, this new reader completes the next generation of our SigNature DNA platform, focusing on our strengths in DNA authentication," stated Dr. Benjamin Liang, Chief Technology Officer, APDN. "Because our markers are botanically derived, we offer a green, environmentally safe technology."

In 2008, APDN began using optical markers in combination with SigNature DNA enabling quick detection using commercially available readers. Given our experience to date with these readers, APDN's scientific team has worked with the SensorCat to prototype a new reader specifically to meet APDN's unique requirements. Phase 2, which is currently underway, will refine the design and portability of this device for the broadest usage possible. It is anticipated that this final phase will be completed by the end of this year.

This proprietary new detector extends the array of instant detection devices currently used by APDN and its customers to detect the presence of our patent-pending DNA-reporter adducts. It will detect multiple adducts from a single device and with higher specificity.

About APDN

APDN sells patented DNA security solutions to protect products, brands and intellectual property from counterfeiting and diversion. SigNature DNA is a botanical mark used to authenticate products in a unique manner that essentially cannot be copied. APDN also provides BioMaterial GenoTyping™ by detecting genomic DNA in natural materials to authenticate finished products. Both technologies protect brands and products in a wide range of industries and provide a forensic chain of evidence that can be used to prosecute perpetrators. To learn more, go to (www.adnas.com).

The statements made by APDN may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K, filed on December 16, 2008 and our subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

SOURCE Applied DNA Sciences, Inc.
INVESTOR RELATIONS: Debbie Bailey, 631-444-8090, fax: 631-444-8848/
MEDIA RELATIONS: Janice Meraglia 631-444-6293
/FCMN Contact: info@adnas.com /
/Web site: <http://www.ADNAS.com> /